Onward Medical N.V. (EBR:ONWD)

Market Cap	152.62M -18.0%
Revenue (ttm)	8.42M +210.1%
Net Income	-45.27M
EPS	-0.85
Shares Out	69.53M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	431,190
Open	2.285
Previous Close	2.230
Day's Range	2.125 - 2.285
52-Week Range	2.020 - 4.790
Beta	0.81
Analysts	Strong Buy
Price Target	9.20 (+319.13%)
Earnings Date	Nov 3, 2026

About Onward Medical

Onward Medical N.V., a medical technology company, develops and commercializes therapies to enable functional recovery for people with spinal cord injury (SCI) in the United States, Europe, and internationally. The company offers ARCEX System, an external stimulator that is intended to improve hand strength and sensation following SCI; ARCIM System, an implantable system currently used to explore potential indications in clinical feasibility studies; ARCBCI System, an implantable system currently being investigated to enable thought driven move...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 137
• Stock Exchange: Euronext Brussels
• Ticker Symbol: ONWD

Financial Performance

In 2025, Onward Medical's revenue was 5.41 million, an increase of 211.33% compared to the previous year's 1.74 million. Losses were -41.79 million, 17.0% more than in 2024.

Analyst Summary

According to 5 analysts, the average rating for ONWD stock is "Strong Buy." The 12-month stock price target is €9.20, which is an increase of 319.13% from the latest price.

Price Target

€9.20

(319.13% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 30, 2026

Data Sources Report a data error